| Document |
Document Title |
|
WO/2024/018188A1 |
The present invention relates to virus-like particle (VLP) that include one or more viral capsid protein heterodimer(s) each comprising a first monomer encoded by a first amino acid sequence and a second monomer encoded by a second amino...
|
|
WO/2024/020242A1 |
Nanoparticles comprising p52K and nucleic acids and/or proteins of interest which self-assemble to form a p52K nucleic acid and/or p52K protein complexes are disclosed. The nanoparticles find use, for example, in the delivery of the afor...
|
|
WO/2024/020388A1 |
Disclosed herein are formulations of small molecule GIP/GLP-1 dual receptor agonists and uses thereof.
|
|
WO/2024/017423A1 |
The invention relates to a peptide identified as SEQ ID NO: 1, for use in the manufacture of a medicine for the treatment of a disease associated with apolipoprotein A-l (Apo-Al) or transthyretin (TTR) involvement. In particular, the pep...
|
|
WO/2024/017379A1 |
A preparation method for a polyethylene glycol conjugate of an active polypeptide or protein, comprising a step of mixing an active polypeptide or protein with polyethylene glycol and reacting same, wherein the polyethylene glycol contai...
|
|
WO/2024/017998A1 |
The present invention relates to an agonist of the colony stimulating factor 1 receptor (CSF1R) for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression in a subject and to pharmaceutical composition...
|
|
WO/2024/019533A1 |
The present disclosure relates to a pharmaceutical composition for treating, preventing and/or ameliorating spinal muscular atrophy (SMA) and a method of administration thereof. A pharmaceutical composition for treating, preventing and/o...
|
|
WO/2024/019495A1 |
The present invention relates to a pharmaceutical composition for treating or preventing atopic dermatitis, the pharmaceutical composition comprising iCP-NI. The pharmaceutical composition makes it possible to administer iCP-NI, previous...
|
|
WO/2024/016740A1 |
Provided is a biosynthesis-based preparation method for a structural material of the human body. A polypeptide of the present application contains the structure of a C-terminal region of (repeating unit)n or (repeating unit)n-; the repea...
|
|
WO/2024/020372A1 |
Disclosed herein are small molecule GLP-1 receptor agonist compounds, pharmaceutical compositions, and the use and preparation thereof.
|
|
WO/2024/019984A1 |
Disclosed herein is a cytokine receptor switch polypeptide comprising an extracellular domain comprising a cytokine binding domain from a first cytokine receptor, wherein the first cytokine receptor is an IL21 receptor, a transmembrane d...
|
|
WO/2024/020083A2 |
Disclosed are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease...
|
|
WO/2024/018245A1 |
Diabetic kidney disease is associated with impaired podocyte autophagy and subsequent podocyte injury. In the present invention, the inventors investigated how the calcium channel TRPC6 and the cysteine protease calpains impair podocyte ...
|
|
WO/2024/020558A1 |
Described herein is a hydrogel including a hydrogel polymer; a crosslinker crosslinking the hydrogel polymer; a biomolecule attached to the hydrogel polymer; and water. In the hydrogel, the biomolecule is attached to the hydrogel polymer...
|
|
WO/2024/018036A1 |
The present invention relates to a platform based on unicellular algae, grown in a controlled environment, which serve as a biofactory for the production of biologically active metabolites.
|
|
WO/2024/018062A1 |
The present invention provides immunoconjugates comprising an antigen and an F-actin-binding moiety. These immunoconjugates promote the presentation of antigens. The invention also provides vaccines that comprise or encode conjugates tha...
|
|
WO/2024/017192A1 |
Provided in the present invention are a drug delivery system comprising blood cells, and a new method for preparing same by means of modifying red blood cell membranes. The present invention also relates to a method for treating diseases...
|
|
WO/2024/020302A2 |
Methods of treating a metabolic disorder in a subject are provided. Aspects of the method include enhancing extracellular Carboxylesterase 2 (CES2) activity in the subject in order to treat the subject for the metabolic disorder. Also pr...
|
|
WO/2024/019976A1 |
The present disclosure relates to methods for treating cancer/inhibiting tumor growth in a patient in need thereof comprising administering to the patient an effective amount of Glatiramer acetate (GA) and an effective amount of an immun...
|
|
WO/2024/017139A1 |
The present invention provides a pharmaceutical composition, comprising a GLP-I receptor agonist or an analog thereof, and further comprising one or more of the following components: a pro-penetrating agent, a basic substance, and an adh...
|
|
WO/2024/017844A1 |
The present invention refers to the new use of a glucagon-like peptide (GLP-1) agonist for treating loss of smell.
|
|
WO/2024/019127A1 |
This hyaluronic acid derivative pharmaceutical composition comprises (A) a hyaluronic acid derivative to which a hydrophobic group is introduced, (B) an association accelerator, and (C) an active ingredient. It is preferable that the (B)...
|
|
WO/2024/020159A1 |
The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit mutants of Kirsten rat sarc...
|
|
WO/2024/017219A1 |
Disclosed are a tumor microenvironment-activated cytokine IFN-α and use thereof. After cysteine mutation of IFN-α, IFN-α is joined to a substrate and a mask body that can be recognized and cleaved by substances highly expressed by tum...
|
|
WO/2024/018374A1 |
The present invention relates to pharmaceutical compositions/formulations providing mucolytic effect. More particularly, the present invention relates to pharmaceutical compositions/formulations comprising synergistic combination of Lact...
|
|
WO/2024/020366A1 |
Disclosed herein are improved broad-spectrum nanozymes for targeting RNA. The disclosed nanozymes are synthesized using recombinant ribonuclease with site-specific cysteine-substituted mutations that can be covalently functionalized with...
|
|
WO/2024/019118A1 |
This hyaluronic acid derivative drug composition contains an active ingredient that is suspended in an aqueous carrier containing a hyaluronic acid derivative. The active ingredient is in the form of fine particles having a molecular wei...
|
|
WO/2024/017845A1 |
The invention relates to a product suitable for the treatment of tear film deficiency in dry eye disease and a method for manufacturing the product. The invention also relates to a product for use in the treatment of tear film deficiency...
|
|
WO/2024/018037A1 |
The present invention relates to a microalgae product capable of expressing glucagon-like peptide (GLP), preferably GLP-2, and its use in the pharmaceutical or nutraceutical field in the treatment and prevention of disorders affecting th...
|
|
WO/2024/020594A1 |
Disclosed are isolated nanoparticles composed of an extracellular matrix which comprises at least one heparin binding domain and nucleic acid or polyphosphate, as well as compositions comprising the nanoparticles and methods of treating ...
|
|
WO/2024/019026A1 |
The present invention provides a pharmaceutical composition containing a compound represented by formula (I), a salt thereof, or a solvate thereof. The present invention uses, as a disintegrant, a partially pregelatinized starch, carmell...
|
|
WO/2024/019642A1 |
The invention relates to biotechnology and medicine, and more particularly to oncology, and can be used for treating tumours. Proposed is a hybrid protein structure containing at the N-terminus of a polypeptide chain a receptor-specific ...
|
|
WO/2024/020431A1 |
A cell culture medium is disclosed. The cell culture medium comprises: a species-specific cell culture medium comprising: bFGF of the species, PDGF-BB of the species, and EGF of the species; and serum of the species. Further disclosed is...
|
|
WO/2024/019057A1 |
The purpose of the present invention is to provide an agent for improving intestinal flora, the agent being capable of improving intestinal flora by increasing the number of bacteria belonging to the genus Bifidobacterium and/or the genu...
|
|
WO/2024/016072A1 |
The present disclosure relates to methods for reproductive management of mammalian animals using a GnRH antagonist such as Cetrorelix. Specifically, the GnRH antagonist can be used for synchronizing follicular wave emergence in a populat...
|
|
WO/2024/018450A1 |
The present disclosure concerns formulations for topical ocular delivery of high concentrations of cyclosporin. The formulations comprise at least 0.1 wt% cyclosporin carried in a plurality of nanostructures in the form of nanodroplets d...
|
|
WO/2024/017958A1 |
The invention relates to a protein formulation comprising a protein formulation comprising a protein and a protective agent, said protective agent comprising (i) at least one amine and/or an ammonium group and (ii) at least one metal pre...
|
|
WO/2024/018398A1 |
The subject matter of the invention is a lipooligourea of the formula (1) FA-Pheu-Xaa1u-Xaa2u-Leuu-Xaa3u-NH2 (1) wherein FA is a linear or branched carboxylic acid residue containing 6 to 15 carbon atoms in the alkyl chain; Xaa1u is eith...
|
|
WO/2024/019553A1 |
The present invention relates to: a method for increasing the half-life of a botulinum toxin type A light chain (AUT-BT-LC) protein, the method comprising substituting one or more lysine residues present in the amino acid sequence of the...
|
|
WO/2024/020135A1 |
An in vitro method of quantifying an estimated dosage of at least one endogenous component from a human placental membrane allograft to a subject in need thereof in vivo during a predetermined time period.
|
|
WO/2024/018369A1 |
The present invention is directed to compositions of novel, non-naturally occurring IL-12 variants, homodimeric IL-12 Fc fusion proteins, and heterodimeric IL-12 Fc fusion proteins, as well as methods of making and using such compositions.
|
|
WO/2024/015822A1 |
Provided herein is a method for treating Parkinson's disease (PD). The method can include identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating PD.
|
|
WO/2024/012503A1 |
The present invention provides a composition based on three factors and used for restoring viability of cells, tissue, or organs of a subject, and a method for using the composition to restore viability of the cells, tissue, or organs of...
|
|
WO/2024/011289A1 |
The present invention relates to novel therapeutic compositions and methods for treating cancer. In particular, the use of proteinaceous inhibitors, including novel bicyclic peptide inhibitors, for use in treating cancer.
|
|
WO/2024/015930A1 |
Disclosed are protein-like polymers and uses thereof. The protein-like polymers generally comprise a polymer of formula (FX1). The polymer of formula (FX1) in some aspects comprises a peptide that (i) inhibits aggregation of, (ii) accele...
|
|
WO/2024/015705A1 |
Provided herein is an AAV2 vector encoding SEQ ID NO: 4 as the optogenetic protein, and methods of use for e.g., retinitis pigmentosa.
|
|
WO/2024/014986A1 |
The invention relates to a magnesium complex of the peptide HAEE described by the formula [Mg(HAEE)]mXn, where Mg is a doubly-charged magnesium (II) cation, m=1 for singly-charged and doubly-charged anions, m=3 for triply-charged anions,...
|
|
WO/2024/015797A1 |
The present disclosure relates to peptide having a sequence comprising: Z1X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15-NH2 (SEQ ID NO: 1), And to their isomers, pharmaceutically acceptable salts, or prodrugs thereof, methods of use, and methods ...
|
|
WO/2024/015857A2 |
Provided herein are modified caveolin-1 (Cav-1) peptide and pharmaceutical formulations and methods of using the peptide or formulations for treating a subject in need thereof. In particular, provided herein are modified Cav-1 peptide fo...
|
|
WO/2024/014980A1 |
The invention relates to a monosubstituted or disubstituted potassium salt of the peptide HAEE, where HAEE is a synthetic peptide that is acetylated at the N-terminus and amidated at the C-terminus and has the amino acid sequence His-Ala...
|
